Aktienanalyse zu Apyx Medical Inc (APYX)APYXApyx Medical Inc

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp is a good buy right now due to its recent earnings performance and positive growth outlook. The current price is $3.08, significantly lower than the analyst price target of $6, indicating a potential upside of 94%. Additionally, the company reported a 33% year-over-year revenue increase in Q1 2026, reaching $12.5 million, and raised its 2026 revenue guidance to between $59 million and $60 million, showcasing strong market confidence. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.